Liquidia (NASDAQ:LQDA) CAO Dana Boyle Sells 1,600 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) CAO Dana Boyle sold 1,600 shares of the stock in a transaction on Monday, July 27th. The stock was sold at an average price of $87.53, for a total transaction of $140,048.00. Following the sale, the chief accounting officer owned 167,919 shares of the company’s stock, valued at approximately $14,697,950.07. This represents a 0.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Dana Boyle also recently made the following trade(s):

• On Monday, July 13th, Dana Boyle sold 9,002 shares of Liquidia stock. The stock was sold at an average price of $71.51, for a total transaction of $643,733.02.

Liquidia Stock Performance

NASDAQ LQDA opened at $86.82 on Thursday. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.03 and a current ratio of 2.22. The firm has a market cap of $7.72 billion, a PE ratio of 620.19 and a beta of 0.55. Liquidia Corporation has a one year low of $16.82 and a one year high of $91.10. The firm’s fifty day moving average is $72.81 and its two-hundred day moving average is $51.36.

Liquidia (NASDAQ:LQDA) last announced its earnings results on Monday, May 11th. The company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.11. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The business had revenue of $132.87 million during the quarter, compared to analysts’ expectations of $119.44 million. Liquidia’s revenue was up 4187.1% compared to the same quarter last year. Analysts expect that Liquidia Corporation will post 3.02 earnings per share for the current year.

Key Headlines Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia will report its second-quarter 2026 financial results on August 12, 2026. The update should provide investors with insight into YUTREPIA sales, operating performance and the company’s outlook. Liquidia Second Quarter 2026 Results Announcement
• Positive Sentiment: LifeSci Capital maintained a Buy rating, while Buckley Capital Advisors cited potential upside of more than 50% based on a prospective YUTREPIA ruling and possible buyout interest. These views support the bullish case, although they depend on regulatory and strategic outcomes. LifeSci Capital Buy Rating Buckley Capital Liquidia Investor Letter
• Neutral Sentiment: Recent coverage highlights a valuation debate: YUTREPIA could drive substantial growth, but patent risks and the stock’s elevated valuation may limit further gains. Shares trade at roughly 620 times earnings, making execution especially important.
• Negative Sentiment: Several insiders reported sales. Director Stephen Bloch sold 178,596 shares for about $15.2 million across July 20–23, while Jason Adair and Chief Accounting Officer Dana Boyle sold smaller amounts on July 27. The latter transactions were conducted under Rule 10b5-1 plans to cover tax withholding, reducing their negative significance; nevertheless, the director’s larger sales may encourage profit-taking concerns. Liquidia Insider Sales SEC Filing

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on LQDA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Liquidia in a research report on Friday, July 17th. Bank of America reissued a “neutral” rating and issued a $79.00 target price (up from $64.00) on shares of Liquidia in a report on Monday, June 29th. Royal Bank Of Canada set a $130.00 price target on Liquidia in a research note on Friday, July 24th. BTIG Research increased their price target on Liquidia from $59.00 to $109.00 and gave the stock a “buy” rating in a report on Monday, June 22nd. Finally, Wells Fargo & Company increased their price target on Liquidia from $51.00 to $62.00 and gave the stock an “overweight” rating in a report on Tuesday, May 12th. Three research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $86.18.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in LQDA. Handelsbanken Fonder AB purchased a new stake in Liquidia in the 2nd quarter valued at approximately $1,993,000. Fulcrum Equity Management acquired a new position in Liquidia during the 2nd quarter worth approximately $399,000. Fluent Financial LLC purchased a new position in shares of Liquidia during the 2nd quarter worth approximately $287,000. FNY Investment Advisers LLC purchased a new position in shares of Liquidia during the 2nd quarter worth approximately $1,395,000. Finally, Seven Fleet Capital Management LP lifted its holdings in shares of Liquidia by 124.5% in the 1st quarter. Seven Fleet Capital Management LP now owns 204,876 shares of the company’s stock valued at $7,732,000 after buying an additional 113,609 shares during the period. 64.54% of the stock is owned by hedge funds and other institutional investors.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).